Barcelona, July 27th 2018

SIGNIFICANT EVENT

Almirall receives positive CHMP opinion for tildrakizumab for the treatment of patients with moderate-to-severe chronic plaque psoriasis

Almirall, S.A. ("Almirall"), pursuant to article 17 of Regulation (EU) No. 596/2014 on market abuse and article 228 of the restated text of the Securities Market Act approved by the Royal Legislative Decree 4/2015, of 23 October and related provisions, hereby announces that:

The **Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the regulatory approval of tildrakizumab, under the brand name ILUMETRI®**, an investigational humanized, high-affinity IL-23p19 monoclonal antibody for adults with moderate-to-severe chronic plaque psoriasis.

Tildrakizumab is a **cutting-edge biological drug** due to its **specific mechanism of action**. It has been designed to selectively **block the p19 subunit of interleukin-23 (IL-23)**, an upstream inflammatory mediator with regulatory properties and it acts by modifying the pathogenesis of the disease with limited impact on the rest of the immune system.

The CHMP positive opinion is based on reSURFACE 1 and 2 positive results, presented for the first time in October 2016 at the 25th European Academy of Dermatology and Venerology (EADV) Congress. Those pivotal phase III clinical trials, which included over 1,800 patients from more than 200 clinical sites worldwide, showed that tildrakizumab has a high level of safety and efficacy.

Tildrakizumab is the result of the licensing agreement reached between Almirall and Sun Pharma for the development and commercialization of this therapy for psoriasis in Europe. Last March, Sun Pharma received the Food and Drug Administration (FDA) approval for tildrakizumab in the United States for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The European Commission (EC) generally follows the recommendations of the CHMP (EMA) and delivers its final decision thereafter. The approval of ILUMETRI® (tildrakizumab) is expected in approximately 60 days and its forthcoming launch in Europe by Almirall will be in late 2018.

Please find attached the Press Release.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com